Core Viewpoint - 嘉应制药's financial performance showed a decline in 2024, but there are signs of recovery in Q1 2025 following strategic changes in management and new investments [1][2][3] Financial Performance - In 2024, 嘉应制药 reported revenue of 376 million yuan, a decrease of 29.46% year-on-year, and a net profit of 20.61 million yuan, down 39.94% [1] - For Q1 2025, the company achieved revenue of 122 million yuan, an increase of 28.83% year-on-year, and a net profit of 15.40 million yuan, a significant rise of 197.23% [1] Strategic Changes - In July 2024,养天和 acquired a 7% stake in 嘉应制药, becoming the second-largest shareholder [3] - Following the election of a new board and management team in August 2024, the company saw immediate improvements in its financial performance [3] Product and Market Position - 嘉应制药 offers over 70 drug varieties, with notable products recognized as "Guangdong Province Famous Products" [2] - The company launched new products in 2024, contributing to a rapid increase in sales [2] Future Outlook - 嘉应制药 plans to stabilize production, optimize supply systems, and enhance market share in 2025 [3]